Stocks to Watch (FOLD,BX,BANF,SCLN)

Amicus Therapeutics, Inc. (NASDAQ: FOLD) fell 24.71% to $6.40 after  announced preliminary results from its Phase 2 randomized, open-label study to assess the safety, tolerability and preliminary efficacy of its investigational drug, Plicera (afegostat tartrate), in treatment-naive adult patients with type 1 Gaucher disease. Two dose regimens of Plicera (225 mg three days on/four days off and seven days on/seven days off) were studied during this six month trial. While all patients enrolled experienced an increase in the level of the target enzyme (GCase) as measured in white blood cells, clinically meaningful improvements in key measures of disease were observed in just one of the eighteen patients who completed the study.

After Friday's closing bell, The Blackstone Group L.P. (NYSE: BX) reportedly was close to a deal to acquire Anheuser-Busch InBev NV (EBR: ABI) theme parks unit for $2.5 billion to $3 billion. Sale of the Busch Entertainment unit, which owns such properties as Sea World and the Busch Gardens parks, has been regarded by some as InBev's plan to help pay for its acquisition of Anheuser-Busch last year, The Wall Street Journal reported in its online edition. The deal could also be announced as early as next week, the Journal said

BancFirst Corporation (NASDAQ: BANF), the bank holding, said it agreed to buy First Jones Bancorporation for an undisclosed amount to expand business in Oklahoma. Friday, the stock closed at $18.08.

SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) fell 13.25 % in aftermarket to $3.60. The drugmaker said it discontinued a study of its experimental drug for pancreatic cancer after a recommendation by a safety review committee.